Key Takeaways From Gilead Sciences Analyst Ratings

Analysts' ratings for Gilead Sciences GILD over the last quarter vary from bullish to bearish, as provided by 10 analysts.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of $79.0, a high estimate of $105.00, and a low estimate of $69.00. Highlighting a 3.92% decrease, the current average has fallen from the previous average price target of $82.22.

Investigating Analyst Ratings: An Elaborate Study

The analysis of recent analyst actions sheds light on the perception of Gilead Sciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gilead Sciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Gilead Sciences compared to the broader market.
• Price Targets: Analysts predict movements in price targets, offering estimates for Gilead Sciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Gilead Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Gilead Sciences analyst ratings.

Discovering Gilead Sciences: A Closer Look

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences's Financial Performance

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Gilead Sciences's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.26%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Gilead Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -62.37% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Gilead Sciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -20.66%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Gilead Sciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -7.04%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average. With a ratio of 1.44, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.